Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Ladarixin 400 mg Twice a Day as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Overweight Insulin-resistant Type 1 Diabetic Patients

Objectives Primary study objective: To determine whether orally-administered ladarixin versus placebo adjunctive therapy improves insulin sensitivity in overweight, insulin-resistant (IR) type 1 Diabetic (T1D) adult subjects.

Secondary study objectives: To determine whether orally-administered ladarixin versus placebo adjunctive therapy is safe and well-tolerated in overweight, IR T1D adult subjects.

Study Overview

• Status: Withdrawn
• Conditions: Type I Diabetes
• Intervention / Treatment: Drug: Ladarixin; Other: Placebo

Detailed Description

This study is a randomized, placebo-controlled, double-blinded, 2-arm, 2-period crossover phase II trial using the CXCR1/CXCR2 chemokine receptor antagonist ladarixin versus placebo as adjunctive therapy to insulin to improve insulin sensitivity as well as glucometabolic outcomes in adult, insulin-requiring, overweight, IR T1D patients.

This trial will randomize 38 male and female patients 21-65 years of age, inclusive, with established insulinrequiring T1D and IR. After a 2:1 randomization into a treatment sequence (either ladarixin followed by placebo, or placebo followed by ladarixin, respectively), patients will be followed up for a maximum of 53 weeks.

The study database will be locked when the last patient randomized has completed visit 9 (week 52/53) and data have been cleaned.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15212
      • Institute of Cellular Therapeutics Allegheny Health Network

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. clinical diagnosis of autoimmune T1D as documented by positive T1D diabetes-related autoantibodies [the presence at diagnosis of at least one or more of - Insulin autoantibodies (IAA), Anti-GAD (GAD65), Anti-IA2 (IA2), Zinc Transporter 8 (ZnT8) must be documented from medical records or new laboratory measurement (not including IAA)];
2. age 21-65 years at the time of consent;
3. T1D duration =>5 years;
4. current insulin standard of care (ISOC), either use of an insulin pump or a stable dose level and dose frequency (i.e. established dose range that does not fluctuate beyond 1SD of the median over a period of the last two months prior to enrollment), multiple daily injections of insulin (at least 3 injections per day) for the last two months prior to enrollment, with no plans to switch the modality of insulin administration during the 4 months following screening (e.g., injection user switching to a pump, pump user switching to injections);
5. HbA1c between 7.5%-10.0%, inclusive, as per results of screening laboratory measurement;
6. evidence of IR based on a total daily insulin dose >0.8 U/kg/ day and/or a screening estimated glucose disposal rate (eGDR) < 9 mg/kg/min 1-3 value strongly indicative of IR, sex- and ageadjusted;
7. subject is overweight or obese with a BMI of between 25-40 kg/m2, inclusive;
8. ability to comply with all protocol procedures for the duration of the study, including scheduled follow-up visits and examinations, and willing to be contacted by clinical trial staff;
9. provision of written informed consent prior of any study-related procedure not part of standard medical care.

Exclusion Criteria:

1. patients with known or suspected hypersensitivity to non-steroidal anti-inflammatory drugs or any excipient of the investigational medicinal products (e.g. lactose and croscarmellose) as well as patients with congenital lactase deficiency, galactosaemia or glucose-galactose intolerance will have to be excluded;
2. use of non-insulin medications for adjunctive blood glucose control (e.g: antidiabetic agents such as metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors, SGLT-2 inhibitors or amylin);
3. use of medications for weight reduction (such as: Belviq (lorcaserin), Qsymia (Phentermine + topiramate), Orlistat (xenical));
4. use of a medication such as stimulants, antidepressants and/or psychotropic agents that could affect weight gain or glycemic control of T1D;
5. subject is on treatment with drugs metabolized by CYP2C9 with a narrow therapeutic index [i.e., phenytoin, warfarin, and high dose of amitriptyline (>50 mg/day)];
6. any medications known to influence glucose tolerance (e.g. beta-blockers, angiotensin-converting enzyme inhibitors, interferons, quinidine antimalarial drugs, lithium, niacin, etc.);
7. evidence of cardiac QTcF > 470 msec and/or any history of significant cardiovascular disease/abnormality;
8. any condition, including unstable dietary approach and disordered eating behaviour patterns, that in the judgment of the investigator will adversely affect patient's safety or the completion of the protocol or otherwise confound study outcome;
9. pregnancy (females) based on serum test (quantitative beta hCG) at screening; unwillingness to use effective contraceptive measures up to 2 months following trial discharge (females and males);effective contraceptive measures include a hormonal birth control (e.g. oral pills, long term injections, vaginal ring, patch); the intrauterine device (IUD); a double barrier method (e.g. condom or diaphragm plus spermicide foam).
10. clinical diagnosis of celiac disease that is in poor control as defined by most recent tissue transglutaminase (tTG) that is in the abnormal range;
11. history of ≥1 Diabetic Ketoacidosis (DKA) events in the past 6 months;
12. history of ≥1 severe hypoglycemic events (cognitive impairment that required assistance to treat) in the past 6 months;
13. hypoalbuminemia defined as serum albumin < 3 g/dL ;
14. hepatic dysfunction defined by increased ALT/AST > 3 x upper limit of normal (ULN) and increased total bilirubin > 3 mg/dL [>51.3 μmol/L];
15. moderate to severe renal impairment calculated by estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73 m2 as determined using Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) creatinine equation;
16. poor accessibility to veins for blood collection;
17. past (within 1 month prior to randomization) or current administration of any immunosuppressive medications (including oral, inhaled or systemically injected steroids) and use of any investigational agents, including any agents that impact the immune response or the cytokine system;
18. condition which interferes with the ability to accurately determine glycated HbA1c. Examples include: Genetic variants (e.g. HbS trait, HbC trait), elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure); Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g., recovery from acute blood loss, hemolytic anemia); Iron deficiency anemia, iron replacement therapy;
19. significant systemic infection during the 4 weeks before the first dose of study drug (e.g., infection requiring hospitalization, major surgery, or i.v. antibiotics to resolve; other infections, e.g., bronchitis, sinusitis, localized cellulitis, candidiasis, or urinary tract infections, must be assessed on a case-bycase basis by the investigator regarding whether they are serious enough to warrant exclusion).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ladarixin - placebo; In this arm the treatment sequence is ladarixin 400 mg twice-a-day, followed by placebo, as adjunctive therapy to insulin in overweight, IR, T1D patients. IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Ladarixin 24 weeks, washout 21 days, Placebo 24 weeks).	Drug: Ladarixin; Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).; Other Names: LDX; Other: Placebo; Placebo is administered with the same schedule of Ladarixin.
Experimental: Placebo - Ladarixin; In this arm the treatment sequence is placebo followed by ladarixin 400 mg twice-a-day, as adjunctive therapy to insulin in overweight, IR, T1D patients. IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Placebo 24 weeks, washout 21 days, Ladarixin 24 weeks).	Drug: Ladarixin; Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).; Other Names: LDX; Other: Placebo; Placebo is administered with the same schedule of Ladarixin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The mean difference in glucose infusion rate (GIR) from baseline	The glucose infusion rate (GIR) is a measure of the rate at which the patient receives intravenous administration of dextrose, which increases blood sugar levels. GIR is expressed in mg per kilogram body weight per minute (mg/Kg/min).	Week 25 of each treatment period (visits 4 and 8)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline of HbA1c levels	In this study glycated hemoglobin (HbA1c) must be between 7.5%-10.0%, inclusive, as per results of screening laboratory measurement.	Week 25/26 (no later than 10 days after the last IMP dose) of each treatment period (visits 5 and 9)
Change in average (previous 3 days) daily insulin requirements	In this study insulin requirement is calculated as IU/kg/day averaged over the previous 3 days.	Week 25/26 (no later than 10 days after the last IMP dose) of each treatment period (visits 5 and 9)

Collaborators and Investigators

• Sponsor: Dompé Farmaceutici S.p.A
• Investigators: Principal Investigator: Nick Giannoukakis, PhD, Allegheny General Hospital and West-Penn Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2021
• Primary Completion (Estimated): June 1, 2023
• Study Completion (Estimated): June 1, 2023

Study Registration Dates

• First Submitted: August 30, 2021
• First Submitted That Met QC Criteria: August 30, 2021
• First Posted (Actual): September 5, 2021

Study Record Updates

• Last Update Posted (Actual): December 22, 2023
• Last Update Submitted That Met QC Criteria: December 21, 2023
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: Overweight; Type I diabetes; Insulin-resistance
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Hyperinsulinism; Diabetes Mellitus, Type 1; Insulin Resistance
• Other Study ID Numbers: LDX0121

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No